 HIGHLANDS RANCH, Colo., Oct. 13, 2021 GLOBE NEWSWIRE -- Vivos Therapeutics, Inc . the Company or Vivos NASDAQ: VVOS, a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea OSA, today announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in pediatric patients after undergoing treatment using the Companys FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. 